Previous 10 | Next 10 |
Theratechnologies (THTX): Q2 GAAP EPS of -$0.07 in-line.Revenue of $17.79M (+3.7% Y/Y) misses by $3.24M.Press Release For further details see: Theratechnologies EPS in-line, misses on revenue
MONTREAL, July 15, 2021 (GLOBE NEWSWIRE) -- Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported financial results for the second quarter ended M...
MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- In a release issued this morning, Wednesday, June 30, 2021, under the same headline, by Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), please note that in the last sentence of the first paragraph, the date should be Thursday, July 15, 2021,...
MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quar...
Theratechnologies (THTX) announces the appointment of Frank Holler as a new independent member to its board of directors.Holler is currently President & CEO of Ponderosa Capital. He also served as President and CEO of Xenon Pharmaceuticals from 1999 to 2003. For further d...
MONTREAL, June 23, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Frank Holler as a new independent mem...
Demonstrates better anti-metastatic activity compared with docetaxel alone Company to host webcast on its oncology program today at 11:00 a.m. ET MONTREAL, June 21, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biop...
- Webinar on Monday, June 21, 2021 at 11:00 a.m. ET - MONTREAL, June 10, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today an...
MONTREAL, May 31, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or the Company (TSX: TH) (NASDAQ: THTX)), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that Mr. André Dupras is joining ...
Theratechnologies (THTX) announces results from two posters highlighting positive patient experience with Trogarzo. The poster included findings from 30 Trogarzo (ibalizumab-uiyk) patients to assess real-world patient experience and acceptance of IV administration.The survey found that 1...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
THTX Stock Symbol:
NYSE Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...